Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04808440
Other study ID # APHP201463
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 23, 2021
Est. completion date September 7, 2021

Study information

Verified date November 2021
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate intubation conditions with the use of atracurium after a fixed three-minute delay


Description:

The recommended dose of a non-depolarizing curare to facilitate tracheal intubation is twice the active dose 95 (the dose that reduces muscle force by 95%). At this dosage, curarization of the laryngeal adductors allowing relaxation and abduction (opening) of the vocal cords is considered certain. With atracurium, the dose for intubation is 0.5 mg.kg-1 and the time to full effect is approximately 3 minutes. With the use of newer hypnotics, there are no data evaluating the conditions for intubation after a fixed time of 3 minutes as with current anesthetic practices.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 7, 2021
Est. primary completion date September 7, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult female - Patient to undergo general anesthesia with intubation for scheduled gynecological surgery - Patient informed about the study and not opposed to it Exclusion Criteria: - Patients with severe and morbid obesity (BMI>35kg/m2) - Pregnancy - Patients with difficult intubation - Allergy to atracurium and to any other drug used. - Patient under tutorship / curatorship - Not affiliated with social insurance - Patient with AME

Study Design


Related Conditions & MeSH terms

  • Obesity Female Patients Require General Anaesthesia With Intubation and Atracurium Curarization

Locations

Country Name City State
France Service Anesthésie Réanimation Chirurgicale Hôpital Cochin Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (3)

Debaene B, Beaussier M, Meistelman C, Donati F, Lienhart A. Monitoring the onset of neuromuscular block at the orbicularis oculi can predict good intubating conditions during atracurium-induced neuromuscular block. Anesth Analg. 1995 Feb;80(2):360-3. — View Citation

Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007 Aug;51(7):789-808. — View Citation

Plaud B, Baillard C, Bourgain JL, Bouroche G, Desplanque L, Devys JM, Fletcher D, Fuchs-Buder T, Lebuffe G, Meistelman C, Motamed C, Raft J, Servin F, Sirieix D, Slim K, Velly L, Verdonk F, Debaene B. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020 Feb;39(1):125-142. doi: 10.1016/j.accpm.2020.01.005. Epub 2020 Jan 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Intubation condition The intubating conditions were evaluated on the basis of the consensus conference on Good Clinical Research Practice in Pharmacodynamic Studies of Neuromuscular Blocking Agents. The score used include the following variables: (1) ease of laryngoscopy, (2) vocal cord position, and (3) reaction to the insertion of the endotracheal tube and the cuff inflation (eg, diaphragmatic movement due to patient cough). Each of these variables was rated as (1) excellent, (2) good, or (3) poor. Intubating conditions were scored as excellent if all variables were excellent; the score was good if at least 1 variable was good and the rest were excellent; the conditions were considered poor if any of the variables was rated poor.
Evaluation of intubation conditions with the use of atracurium after a fixed three-minute delay
3 minutes after atracurium injection